ReviewOrphanet journal of rare diseases2025
Autosomal dominant tubulointerstitial kidney disease-UMOD: a short review.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD: Case Report and Disease Update.Diagnostics (Basel, Switzerland) · 2026Article
- A case of ADTKD-UMOD presenting with focal segmental glomerulosclerosis in a young male with a positive family history.BMC nephrology · 2026Article
- Kidney Organoids: Current Advances and Applications.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
ADTKD-UMOD (Autosomal Dominant Tubulointerstitial Kidney Disease - Uromodulin) is a hereditary kidney disease caused by mutations in the UMOD gene, primarily characterized by renal dysfunction and related symptoms. This review aims to explore the clinical characteristics and molecular mechanisms associated with ADTKD-UMOD, highlighting the importance of understanding this condition for improved patient management. We will analyze the latest findings in the field of ADTKD-UMOD research, addressing its etiology, pathogenesis, clinical manifestations, and potential therapeutic strategies. Current research has identified various genetic mutations and their implications, yet challenges remain in fully elucidating the precise mechanisms by which these mutations lead to renal impairment. By synthesizing existing literature and addressing gaps in knowledge, this review seeks to enhance understanding of ADTKD-UMOD and promote effective clinical approaches to management and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.